Articles tagged with Positron Emission Tomography
Researchers at the University of Alberta have discovered that an anti-inflammatory drug, VX-765, can slow disease progression in a preclinical model of multiple sclerosis when delivered intranasally. This new therapy approach has shown promise in preserving myelin and glucose metabolism.
A new intraoperative imaging technique, Cerenkov luminescence imaging (CLI), can accurately assess surgical margins during radical prostatectomy by detecting prostate cancer tissue at the resection margin. CLI has shown high diagnostic accuracy in detecting tumor cells and positive surgical margins.
A Japanese team has developed a simple way to glean more detailed information from standard medical imaging scans by detecting the oxygen concentration of tissues throughout patients' bodies. The upgraded PET scanners may lead to more effective cancer treatment by quickly identifying parts of tumors with aggressive cell growth.
A team of researchers developed an innovative approach to identify and evaluate candidate molecules that can image and track the progression of Parkinson's disease. They screened millions of compounds using a high-throughput computational method, identifying two promising candidates with extremely high binding affinity to alpha-synuclein.
Researchers at Washington University School of Medicine have developed an experimental imaging agent called Galuminox that detects inflammation via positron-emission tomography (PET) scans. The agent has shown promise in imaging inflammation in the lungs of mice with acute lung injury, and its potential uses include cancer treatment an...
A PET brain imaging study found that low aromatase levels in the amygdala are associated with higher BMI and lower self-control. The results suggest a novel method for characterizing estrogen's role in obesity and impairments in self-regulation.
A new study reveals a potential link between brain inflammation and fatigue in multiple sclerosis, using PET imaging to identify specific brain regions correlated with fatigue scores. The findings open new avenues for diagnostic and therapeutic research into the debilitating symptom.
A blood test for Alzheimer's disease has shown high accuracy in detecting the disease, with levels of p-tau217 increasing seven-fold in individuals with Alzheimer's. The test detected tau brain changes 20 years before cognitive impairment in those with a genetic predisposition.
Researchers at Washington University School of Medicine have developed a technique to detect minute amounts of p-tau-217, a protein fragment linked to Alzheimer's disease in the blood. The levels of this protein are elevated during the early stages of the disease and can accurately predict the presence of amyloid plaques in PET scans.
A novel bone imaging approach has established that bone metabolism is abnormally elevated in patients with knee osteoarthritis. This finding provides a new functional measure to assess degeneration of the knee joint, and may help develop interventions to slow or arrest its progression.
Stephen L. Bacharach, PhD, is recognized for his contributions to gated cardiac blood pool imaging, informatics, and data processing. His research has had a significant impact on nuclear medicine and cardiology.
A new molecular imaging approach using PET/MRI has been developed to precisely identify the location of pain generators in chronic pain patients. This approach resulted in a significant modification of management plans for nearly half of the patients, with some receiving invasive procedures.
Researchers used a novel imaging agent to visualize inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction. The study found a systemic inflammatory response, suggesting a potential mechanism for disease progression and therapy response.
A new radiotracer measures synaptic density changes in the brain after stroke, providing an objective and quantitative measure of disease progression. This method may also help detect stroke early and evaluate recovery.
Peter S. Conti, MD, PhD, received the 2020 Benedict Cassen Prize for his pioneering work in radiopharmaceuticals and clinical PET applications for cancer imaging. The award recognizes his contributions to advancing nuclear medicine and molecular imaging.
A new study using uEXPLORER technology successfully detected metastatic cancer in patients, providing high-quality images of tumor behavior. Parametric images showed improved visibility of cancer lesions detection and multi-parametric characterization of tumor metastases.
Carolyn J. Anderson, PhD, has been recognized for her pioneering work in radiometal-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of cancer and other diseases. Her research focuses on developing imaging agents for upregulated receptors on immune cells involved in inflammation related to lung diseases.
Research reveals that age, sex and smoking impact μ-opioid receptor density in brain. Dysfunctions of the brain's opioid system are linked to disorders like addiction and chronic pain.
Researchers from SUTD and international partners developed a theoretical descriptor to quantitatively design PET-based fluorescence probes, accelerating biological research. The descriptor enables the accurate prediction and development of new fluorescent stains for live cell bioimaging.
Researchers have developed a new imaging tool that detects widespread synaptic loss throughout the brain in early stages of Alzheimer's disease. This breakthrough enables scientists to identify areas of specific damage and monitor disease progression.
Researchers compare whole-body diffusion-weighted MRI to FDG PET and find significant agreement in tracking tumor response to therapy, raising the possibility of using DW MRI as a replacement for CT scanning.
A new review study found that three tests - amyloid PET, FDG-PET, and MRI - are highly accurate in distinguishing between Alzheimer's disease and other causes of dementia. These tests show promise in improving diagnosis, but more study is needed for standardization.
A new blood test has been developed to detect Alzheimer's disease, which measures a specific variant of tau protein in ordinary blood samples. The test shows great promise for diagnosing and monitoring the condition early on, particularly in primary care settings.
Researchers create a radiotracer labelled with the fluorine isotope 18F, enabling visualization of special transport proteins often found in cancer cells. The new compound has a relatively short half-life of 110 minutes and can be produced automatically.
Researchers used total-body PET imaging to track the distribution of 89Zr-labeled antibodies in preclinical trials, achieving excellent image quality up to 30 days after injection. The study demonstrates the potential of this technique for extended imaging windows and low-dose radioactivity.
Researchers used PET myocardial perfusion imaging to quantify myocardial blood flow and flow reserve, successfully detecting cardiac allograft vasculopathy and predicting prognosis. The study found MFR had higher accuracy in predicting overall prognosis for cardiac transplant patients.
A new radiopharmaceutical, [55Co]Co-DOTATATE, has been developed to aid in the diagnosis of neuroendocrine tumor metastases. It resulted in superior image contrast and enhanced detection compared to commonly used imaging agents.
A team of researchers at Wake Forest School of Medicine will use a novel brain-imaging technique to image microtubules in the brain, which could potentially predict the onset of Alzheimer's disease. The study aims to identify a biomarker for neural degeneration and cognitive impairment.
A new drug called Myeliviz has been approved for its first human trials to aid multiple sclerosis (MS) diagnoses. The drug targets and binds to myelin, allowing for its imaging by a PET scanner, potentially providing earlier and more accurate diagnoses.
Scientists have developed a method to reduce noise and reconstruct images from raw data, capturing ultrafast whole-body dynamic tracer imaging with improved image quality at a timescale of 100 milliseconds.
Researchers developed a total-body PET/CT scanner with advanced reconstruction techniques to capture radiotracer transport in humans at 100 ms timescales. This approach offers clear images of cardiac blood pool changes throughout the cardiac cycle, enabling real-time motion tracking and neural activity analysis.
A new radiotracer, 68Ga-FAPI-04 PET, can effectively image fibroblast activation after myocardial infarction, identifying a time window during which cardiac fibrosis can be prevented. This technology may aid in the clinical management of patients after a heart attack.
A new study finds that tau protein is a more reliable predictor of brain atrophy in Alzheimer's patients than amyloid plaques. Tau PET imaging technology has the potential to accelerate clinical trials and improve individualized patient care.
Researchers Marcos Barp and Felipe Arretche developed a model predicting rotational energy loss when positrons collide with molecules like CF4 and methane. The model agreed well with experimental results and could improve PET scanning techniques, providing new insights into matter-antimatter interactions.
A study published in Journal of Nuclear Cardiology found that combining Transcendental Meditation with cardiac rehabilitation increases myocardial blood flow by 20.7%. This increase is significantly higher than the 5.8% improvement seen with cardiac rehabilitation alone.
A multi-centre registry trial is testing the use of a new PSMA tracer to detect early recurrence of prostate cancer. The trial provides valuable insights and has already shown promising results for patients like Wayne Smith, who was able to have a shorter round of hormone therapy.
Researchers at UCLA Jonsson Comprehensive Cancer Center identified a new biomarker tracking mitochondrial activity in lung tumors using noninvasive imaging. This level of activity may predict favorable response to complex I inhibitor and inform treatment decisions for individuals with lung cancer.
A team of researchers at the University of Pennsylvania is developing a critical tool for imaging the brains of patients with Parkinson's disease. They plan to use a special type of PET scan to detect the disease early on and provide detailed information about its progression.
A new study finds that 68Ga-DOTATATE PET/CT is a more accurate method for selecting patients with neuroendocrine tumors who may benefit from peptide receptor radionuclide therapy. The imaging modality yields significantly higher Krenning scores and detects eligible patients with smaller lesions.
The study used the 18F-labelled PSMA-1007 radiotracer to detect recurrent and metastatic prostate cancer, which was not identified by conventional diagnostic imaging. The hospital aims to spread nuclear medicine that uses drugs labeled with α-emitting radionuclides for higher therapeutic effects.
Researchers studied tau protein accumulation after a single traumatic brain injury (TBI) in 32 individuals and found increased deposition of tau associated with poorer memory and cognitive performance. Higher tau levels were also linked to more severe neurodegeneration and damage to the brain's white matter.
Researchers have developed a blood test that can detect Alzheimer's disease with 94% accuracy when combined with age and genetic risk factor. The test measures levels of amyloid beta in the blood to predict brain changes, potentially allowing for earlier intervention.
A $47 million grant will incorporate advanced brain imaging into the Alzheimer's Association's U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) clinical trial. The study aims to determine whether lifestyle changes can protect memory in people at risk of developing dementia.
A new imaging diagnosis device called a Compton camera enables simultaneous PET and SPECT scans, reducing time and radiation exposure. Researchers detected and imaged radioactive tracers with improved accuracy, paving the way for new forms of medical analysis.
A Louisiana State University biologist conducted a groundbreaking study using PET scans on wild songbirds to understand the role of dopamine in stress resilience. The research found that dopamine receptors decrease over time during captivity, leading to anxiety-related behaviors.
A new study uses amyloid positron emission tomography to track β-amyloid cerebrospinal fluid and monitor Alzheimer's disease progression over six years. The researchers found a significant correlation between β-amyloid levels and cognitive decline, providing valuable insights into the disease's progression.
A new study by UC Berkeley psychologists links disrupted sleep in 50s and 60s to increased protein tangles in the aging brain, raising the risk of developing Alzheimer's disease. The research highlights the importance of sleep for maintaining a healthy brain into old age.
Researchers have developed ultrasmall nanoclusters with antioxidative properties that can pass through the kidneys' filtration barrier to alleviate clinical symptoms of AKI. Selenium-doped carbon quantum dots also demonstrated effective treatment and prevention of AKI in mice by localizing in the kidneys and eliminating ROS.
A study using PET imaging reveals that women with the ApoE 4 allele are more susceptible than men to tau accumulation in the brain. The study also found that sex modulates the effect of ApoE ε4 on brain tau depositing in individuals with mild cognitive impairment.
A new class of radiopharmaceuticals, named radiohybrids (rh), has been developed for cancer imaging and radioligand therapy (theranostics). These rhPSMA-ligands have a unique feature that both fluorine and the metal are always present, but only one of them is present as a radioactive isotope.
Research shows that adding an interim scan during therapy can help guide patient treatment, predicting survival and tumor response. Interim scans using PSMA PET imaging have shown significant predictive value for overall survival in patients undergoing 177Lu-PSMA radioligand therapy.
Researchers at UNC Lineberger Comprehensive Cancer Center discovered a new way to attach Fluorine-18, a widely used PET imaging isotope, to existing compounds. This breakthrough enables the creation of novel PET agents from existing drugs, opening up possibilities for tracking pharmaceuticals and diagnosing diseases like cancer.
A new study from McGill University and the University of Antwerp has developed a PET imaging platform that allows simultaneous scanning of multiple awake animals. This breakthrough enables unprecedented experimental designs and opens up new avenues for research into brain function, neurochemistry, and behavior.
A team of researchers developed a macrocyclic peptide, HiP-8, that selectively inhibits active Hepatocyte Growth Factor (HGF), a protein promoting cancer cell invasion and survival. HiP-8 shows high affinity for HGF and has potential as a PET imaging probe and anti-cancer drug.
Cardiovascular PET has grown into a staple of contemporary cardiovascular care, with emerging techniques expanding its applications to CAD, CMD, and vascular plaques. The development of new tracers and absolute flow assessment are poised to further improve diagnostic information and treatment outcomes.
Researchers at the University of Zurich have developed a simple and fast method for radiolabelling antibodies against breast cancer using UV light. The new procedure allows for the production of radioactive drugs and diagnostic agents in under 20 minutes, making it a game-changer for PET imaging and targeted radioimmunotherapy.
Researchers found elevated tau protein levels in brain regions affected by CTE in living former NFL players with cognitive and mood symptoms. The study also discovered a correlation between years of tackle football played and tau protein levels.
Researchers have discovered a new PET imaging biomarker that can better predict the progression of Alzheimer's disease. Microglial activation levels, as measured by TSPO-PET imaging, showed a significant correlation with cognitive outcomes in an amyloid mouse model.
A study of 11,400 patients with dementia or mild cognitive impairment found that amyloid PET imaging was associated with changes in clinical management within 90 days. The use of this imaging technique was reported in 55% of MCI patients and 70% of those with dementia.
A nationwide study found that amyloid PET imaging significantly influenced clinical management of patients with mild cognitive impairment and dementia. The technique altered diagnoses and treatment plans in nearly two-thirds of cases, more than double predictions.